eConsent Solutions
-
Empower Patients To Make Informed Decisions
11/8/2022
YPrime’s eConsent platform and patient-centered approach ensure better comprehension of complex information, accelerate enrollment and screening, and improve patient engagement.
-
Patient Engagement By Datacubed Health
2/16/2022
Explore how the Datacubed platform supports eCOA, virtual visits, eConsent and geofencing (a frictionless way to capture adverse event data) in one solution.
-
Informed Decisions, Empowered Patients, & Improved Outcomes
2/23/2023
Boost site/patient discussions and clinical trial efficiency while experiencing a more reliable way to consent patients into a clinical trial with eConsent.
-
One Home for Sites™ Partnership Program Guide
4/7/2024
Learn how your organization can become part of One Home for Sites, the only platform that’s bringing the industry together to help sites survive and thrive, along with their patients.
-
Democratizing Clinical Research With Castor
5/11/2023
Execute your study with Castor using modular solutions or as a platform package.
-
End-To-End Diagnostic Studies Powered By Technology
12/16/2022
Learn why Curebase is the only partner you need to run faster, more efficient real-world diagnostics studies from start to finish.
-
End-To-End Digital Therapeutics Studies Powered By Technology
2/2/2023
Curebase offers a variety of decentralized study models designed and tested for any type of DTx trial.
-
Introducing One Home for Sites™
2/8/2024
One Home for Sites is a vendor-agnostic, sponsor-agnostic, aggregation platform that provides single sign-on and more. Become part of the only industry-wide solution to site tech overload.
-
Medrio eConsent
10/5/2023
Flexible consent technology improves participant comprehension and process oversight. Learn how Medrio’s eConsent solution is empowering organizations to accelerate all aspects of the consent process.
-
How Can Phase 1 Trials Employ eClinical Solutions?
1/8/2024
Uncover how this unified platform is helping sponsors and CROs generate high-quality data, accelerate trials, and rapidly scale to Phase 2 and beyond.